Background: Eosinophils represent a potential therapeutic target in allergic diseases. We previously reported that two clones of anti-CD30 mAbs (HRS-4 and Ber-H8) induced extremely rapid and intense apoptosis in human eosinophils in vitro, but only when the mAbs were immobilized on plates [Matsumoto K, J Immunol 2004;172:2186]. As the initial step towards clinical application of these anti-CD30 mAbs in the treatment of allergic diseases, we made an attempt to clarify two issues; first, whether or not anti-CD30 mAb-coated microspheres can efficiently induce apoptosis in human eosinophils, and second, whether or not these apoptotic eosinophils can be phagocytosed by macrophages without the release of granular proteins. Methods: Purified human eosinophils were treated with anti-CD30 mAb-coated polystyrene microspheres (diameter, 1.44 µm). Apoptosis was determined by annexin V-binding. For the phagocytosis assay, eosinophils were co-cultured with monocyte-derived human macrophages or PMA-pretreated U-937 cells. Phagocytosis was determined by light microscopy and by the eosinophil-derived neurotoxin (EDN) concentration in the supernatant. Results: Anti-CD30 mAb-coated, but not control IgG1-coated microspheres significantly reduced eosinophil survival in a dose-dependent manner. Marked phagocytosis of the apoptotic eosinophils by macrophages was also observed when the eosinophils were treated with anti-CD30 mAb-coated microspheres. The apoptotic eosinophils released large amounts of EDN in the absence of macrophages; however, the EDN levels were significantly decreased when the eosinophils were co-cultured with macrophages. Conclusions: Anti-CD30 mAb-coated microspheres are capable of inducing rapid and strong apoptosis in human eosinophils. Furthermore, the apoptotic eosinophils were also phagocytosed by macrophages with minimal release of the granular proteins.

Keywords:
Eosinophil, Apoptosis, CD30, Microsphere, Macrophage, Phagocytosis, Eosinophil-derived neurotoxin
1.
Gleich GJ, Adolphson CR, Leiferman KM: The biology of the eosinophilic leukocyte. Annu Rev Med 1993;44:85–101.
2.
Weller PF, Lim K, Wan HC, Dvorak AM, Wong DT, Cruikshank WW, Kornfeld H, Center DM: Role of the eosinophil in allergic reactions. Eur Respir J Suppl 1996;22:109s–115s.
3.
Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: biology and role in disease. Adv Immunol 1995;60:151–266.
4.
Ohno I, Nitta Y, Yamauchi K, Hoshi H, Honma M, Woolley K, O’Byrne P, Tamura G, Jordana M, Shirato K: Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1996;15:404–409.
5.
Odemuyiwa SO, Ghahary A, Li Y, Puttagunta L, Lee JE, Musat-Marcu S, Moqbel R: Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase. J Immunol 2004;173:5909–5913.
6.
Ohno I, Ohtani H, Nitta Y, Suzuki J, Hoshi H, Honma M, Isoyama S, Tanno Y, Tamura G, Yamauchi K, Nagura H, Shirato K: Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997;16:212–219.
7.
Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029–1036.
8.
Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ: Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 2005;116:796–804.
9.
Kay AB, Phipps S, Robinson DS: A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004;25:477–482.
10.
Ying S, Meng Q, Taborda-Barata L, Kay AB: Association of apoptosis of neutrophils and eosinophils and their ingestion by macrophages with resolution of the allergen-induced cutaneous late-phase response in atopic human subjects. Proc Assoc Am Physicians 1997;109:42–50.
11.
Haslett C: Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 1999;160:S5–S11.
12.
Tai PC, Sun L, Spry CJ: Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 1991;85:312–316.
13.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, Hansel TT, Holgate ST, Sterk PJ, Barnes PJ: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356:2144–2148.
14.
Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS: Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199–204.
15.
Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H: Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell 1992;68:421–427.
16.
Romagnani S, Parronchi P, D’Elios MM, Romagnani P, Annunziato F, Piccinni MP, Manetti R, Sampognaro S, Mavilia C, De Carli M, Maggi E, Del Prete GF: An update on human Th1 and Th2 cells. Int Arch Allergy Immunol 1997;113:153–156.
17.
Petkova D, Xaubet A, Picado C, Filella X, Agusti C, Luburich P, Rodriguez-Roisin R: Evaluation of CD30 as a marker for th2 lymphocytes in bronchoalveolar lavage in interstitial lung diseases. Respir Med 2000;94:345–349.
18.
Yamamoto J, Adachi Y, Onoue Y, Kanegane H, Miyawaki T, Toyoda M, Seki T, Morohashi M: CD30 expression on circulating memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 2000;55:1011–1018.
19.
Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM: Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 2000;95:231–240.
20.
Telford WG, Nam SY, Podack ER, Miller RA: CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 1997;182:125–136.
21.
Biswas P, Rovere P, De Filippi C, Heltai S, Smith C, Dagna L, Poli G, Manfredi AA, Ferrarini M: Engagement of CD30 shapes the secretion of cytokines by human gamma delta T cells. Eur J Immunol 2000;30:2172–2180.
22.
Cambiaggi A, Cantoni C, Marciano S, De TD, Pileri S, Tazzari PL, Stein H, Ferrini S: Cultured human NK cells express the Ki-1/CD30 antigen. Br J Haematol 1993;85:270–276.
23.
Meerloo T, Parmentier HK, Osterhaus AD, Goudsmit J, Schuurman HJ: Modulation of cell surface molecules during HIV-1 infection of H9 cells: an immunoelectron microscopic study. AIDS 1992;6:1105–1116.
24.
Boiocchi M, De Re V, Gloghini A, Vaccher E, Dolcetti R, Marzotto A, Bertola G, Carbone A: High incidence of monoclonal EBV episomes in Hodgkin’s disease and anaplastic large-cell KI-1-positive lymphomas in HIV-1-positive patients. Int J Cancer 1993;54:53–59.
25.
Horie R, Watanabe T: CD30: expression and function in health and disease. Semin Immunol 1998;10:457–470.
26.
Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004;172:2186–2193.
27.
Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS: Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 1995;86:1437–1443.
28.
Walsh GM, Williamson ML, Symon FA, Willars GB, Wardlaw AJ: Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. Blood 1996;87:2815–2821.
29.
Blaylock MG, Sexton DW, Walsh GM: Ligation of CD45 and the isoforms CD45RA and CD45RB accelerates the rate of constitutive apoptosis in human eosinophils. J Allergy Clin Immunol 1999;104:1244–1250.
30.
Nutku E, Aizawa H, Hudson SA, Bochner BS: Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003;101:5014–5020.
31.
Kato M, Abraham RT, Okada S, Kita H: Ligation of the beta2 integrin triggers activation and degranulation of human eosinophils. Am J Respir Cell Mol Biol 1998;18:675–686.
32.
Hansel TT, De VI, Iff T, Rihs S, Wandzilak M, Betz S, Blaser K, Walker C: An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145:105–110.
33.
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
34.
Munn DH, Cheung NK: Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays. J Exp Med 1989;170:511–526.
35.
Callahan MK, Halleck MS, Krahling S, Henderson AJ, Williamson P, Schlegel RA: Phosphatidylserine expression and phagocytosis of apoptotic thymocytes during differentiation of monocytic cells. J Leukoc Biol 2003;74:846–856.
36.
Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S: Identification of a factor that links apoptotic cells to phagocytes. Nature 2002;417:182–187.
37.
Wu Y, Tibrewal N, Birge RB: Phosphatidylserine recognition by phagocytes: a view to a kill. Trends Cell Biol 2006;16:189–197.
38.
Stern M, Meagher L, Savill J, Haslett C: Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543–3549.
39.
Savill J, Fadok V, Henson P, Haslett C: Phagocytic recognition of cells undergoing apoptosis. Immunol Today 1993;14:131–136.
40.
Nagata S, Nagase H, Kawane K, Mukae N, Fukuyama H: Degradation of chromosomal DNA during apoptosis. Cell Death Differ 2003;10:108–116.
41.
Matsumoto K, Terakawa M, Fukuda S, Kato A, Toki S, Shinohara M, Wakiguchi H, Saito H: CpG oligodeoxynucleotide prolongs eosinophil survival through activation of contaminating B cells and plasmacytoid dendritic cells in vitro. Int Arch Allergy Immunol 2006;140:s42–s50.
42.
Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa’ad AH, Rothenberg ME: Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004;113:115–119.
43.
Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J: Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334–2339.
44.
Noel RJ, Putnam PE, Rothenberg ME: Eosinophilic esophagitis. N Engl J Med 2004;351:940–941.
45.
Simon D, Braathen LR, Simon HU: Anti-interleukin-5 antibody therapy in eosinophilic diseases. Pathobiology 2005;72:287–292.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.